Stem cell technology and computational modelling offer the promise of reducing the current burden of cardiotoxicity assessment.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chi, K. Revolution dawning in cardiotoxicity testing. Nat Rev Drug Discov 12, 565–567 (2013). https://doi.org/10.1038/nrd4083
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4083
This article is cited by
-
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Current Hematologic Malignancy Reports (2017)
-
Evolution of strategies to improve preclinical cardiac safety testing
Nature Reviews Drug Discovery (2016)
-
A high-throughput in vitro ring assay for vasoactivity using magnetic 3D bioprinting
Scientific Reports (2016)
-
Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications
Scientific Reports (2015)
-
Assessing the Arrhythmogenic Potential of New Drugs: A Guide for the Pharmaceutical Physician
Pharmaceutical Medicine (2015)
